AbbVie Inc., a biopharmaceutical company, has filed a definitive additional materials proxy statement with the United States Securities and Exchange Commission (SEC). This filing, pursuant to Section 14(a) of the Securities Exchange Act of 1934, indicates that AbbVie is preparing materials related to upcoming corporate matters that may require a vote by shareholders. The proxy statement is not preliminary and does not require a filing fee, suggesting that it is ready for review by shareholders and the SEC. The document is intended for use in connection with the company's forthcoming decisions and does not constitute soliciting material under §240.14a-12.

AbbVie Inc., a biopharmaceutical company, has filed a definitive additional materials proxy statement with the United States Securities and Exchange Commission (SEC). This filing, pursuant to Section 14(a) of the Securities Exchange Act of 1934, indicates that AbbVie is preparing materials related to upcoming corporate matters that may require a vote by shareholders. The proxy statement is not preliminary and does not require a filing fee, suggesting that it is ready for review by shareholders and the SEC. The document is intended for use in connection with the company's forthcoming decisions and does not constitute soliciting material under §240.14a-12.